{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:38:23Z","timestamp":1787243903946,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD19-CAR T-cell therapy (CART19) causes B-cell aplasia (BCA) and dysgammaglobulinemia but there is a lack of information about the degree of its secondary immunodeficiency. We conducted a prospective study in children and young adults with acute lymphoblastic leukaemia treated with CART19, analysing the kinetics of BCA and dysgammaglobulinemia during therapy, as well as the B-cell reconstitution in those with CART19 loss. Thirty-four patients were included (14 female) with a median age at CART19 infusion of 8.7 years (2.9\u201324.9). Median follow-up after infusion was 7.1 months (0.5\u201342). BCA was observed 7 days after infusion (3\u20138), with persistence at 24 months in 60% of patients. All patients developed a progressive decrease in IgM and IgA: 71% had undetectable IgM levels at 71 days (41\u201399) and 13% undetectable IgA levels at 185 days (11\u2013308). Three of 12 patients\u00a0had protective levels of IgA in saliva. In two of three patients who lost CART19, persistent B-cell dysfunction was observed. No severe infections occurred. In conclusion, BCA occurs soon after CART19 infusion, with a progressive decrease in IgM and IgA, and with less impairment of IgA, suggesting the possibility of an immune reservoir. A persistent B-cell dysfunction might persist after CART19 loss in this population.<\/jats:p>","DOI":"10.1038\/s41409-020-01027-6","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T13:03:23Z","timestamp":1597410203000},"page":"376-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia"],"prefix":"10.1038","volume":"56","author":[{"given":"A.","family":"Dey\u00e0-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alonso-Saladrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9900-9376","authenticated-orcid":false,"given":"A. P.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Faura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Torrebadell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vlagea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Catal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Esteve-Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-1831","authenticated-orcid":false,"given":"S.","family":"Rives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-0018","authenticated-orcid":false,"given":"L.","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"1027_CR1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"1027_CR2","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.","journal-title":"Sci Transl Med"},{"key":"1027_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cell expressing CD19 chimeric antigen receptor for acute lymphoblastic leukemia in children and young adults: a phase 1- dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet."},{"key":"1027_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2017.09.016","volume":"186","author":"C Rossig","year":"2018","unstructured":"Rossig C. CAR T cell immunotherapy in hematology and beyond. Clin Immunol. 2018;186:54\u20138.","journal-title":"Clin Immunol"},{"key":"1027_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nbt0817-691","volume":"8","author":"C Sheridan","year":"2017","unstructured":"Sheridan C. First approval in sight for Novartis\u2019 CAR-T therapy after expert panel vote. Nat Biotechnol. 2017;8:691\u20133.","journal-title":"Nat Biotechnol"},{"key":"1027_CR6","unstructured":"FDA Website. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm581216.htm."},{"key":"1027_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"1027_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"1027_CR9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1027_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1600-065X.2010.00940.x","volume":"237","author":"SA Oracki","year":"2010","unstructured":"Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunol Rev. 2010;237:140\u201359.","journal-title":"Immunol Rev"},{"key":"1027_CR11","unstructured":"Rawstron AC. Immunophenotyping of plasma cells. Curr Protoc Cytom. 2006;Chapter 6:Unit 6.23"},{"key":"1027_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1615\/CritRevImmunol.2014012168","volume":"34","author":"I Bayles","year":"2014","unstructured":"Bayles I, Milcarek C. Plasma cell formation, secretion, and persistence: the short and the long of it. Crit Rev Immunol. 2014;34:481\u201399.","journal-title":"Crit Rev Immunol"},{"key":"1027_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaip.2019.08.012","volume":"8","author":"PJ Maglione","year":"2020","unstructured":"Maglione PJ, Ko HM, Tokuyama M, Gyimesi G, Soof C, Li M, et al. Serum B-cell maturation antigen (BCMA) levels differentiate primary antibody deficiencies. J Allergy Clin Immunol Pract. 2020;8:283\u201391.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1027_CR14","doi-asserted-by":"publisher","first-page":"e26914","DOI":"10.1002\/pbc.26914","volume":"65","author":"A Doan","year":"2018","unstructured":"Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr Blood Can. 2018;65:e26914.","journal-title":"Pediatr Blood Can"},{"key":"1027_CR15","doi-asserted-by":"publisher","first-page":"e28092","DOI":"10.1002\/pbc.28092","volume":"67","author":"DE Arnold","year":"2020","unstructured":"Arnold DE, Maude SL, Callahan CA, DiNofia AM, Grupp SA, Heimall JR. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for b-cell acute lymphoblastic leukemia in pediatric patients. Pediatr Blood Cancer. 2020;67:e28092.","journal-title":"Pediatr Blood Cancer"},{"key":"1027_CR16","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","volume":"38","author":"JA Hill","year":"2019","unstructured":"Hill JA, Giralt S, Torgerson TR, Lazarus HM. CAR-T and a side order of IgG, to go? - Immunolgobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019;38:100596.","journal-title":"Blood Rev."},{"key":"1027_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","volume":"128","author":"VG Bhoj","year":"2016","unstructured":"Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016;128:360\u201370.","journal-title":"Blood"},{"key":"1027_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","volume":"12","author":"M Castella","year":"2018","unstructured":"Castella M, Boronat A, Mart\u00edn-Ib\u00e1\u00f1ez R, Rodr\u00edguez V, Su\u00f1\u00e9 G, Caballero M, et al. Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions. Mol Ther Methods Clin Dev. 2018;12:134\u201344.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1027_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clim.2016.05.006","volume":"169","author":"S S\u00e1nchez-Ram\u00f3n","year":"2016","unstructured":"S\u00e1nchez-Ram\u00f3n S, de Gracia J, Garc\u00eda-Alonso AM, Rodr\u00edguez Molina JJ, Melero J, de Andr\u00e9s A, et al. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency. Clin Immunol. 2016;169:80\u20134.","journal-title":"Clin Immunol."},{"key":"1027_CR20","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","volume":"54","author":"AJ Kansagra","year":"2019","unstructured":"Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, et al. Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transpl. 2019;54:1868\u201380.","journal-title":"Bone Marrow Transpl"},{"key":"1027_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DL Lee","year":"2019","unstructured":"Lee DL, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Trasnplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Trasnplant"},{"key":"1027_CR22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10875-014-0003-x","volume":"34","author":"J Routes","year":"2014","unstructured":"Routes J, Abinum M, Al-Herz W, Bustamante J, Condino-Neto A, De La Morena MT, et al. ICON: The early diagnosis of congenital immunodeficiencies. J Clin Immunol. 2014;34:398\u2013424.","journal-title":"J Clin Immunol"},{"key":"1027_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1155\/2001\/28962","volume":"8","author":"A Maas","year":"2001","unstructured":"Maas A, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cell development. Dev Immunol. 2001;8:171\u201381.","journal-title":"Dev Immunol."},{"key":"1027_CR24","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322\u201331.","journal-title":"Blood."},{"key":"1027_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/bs.ai.2016.03.001","volume":"131","author":"YH Yu","year":"2016","unstructured":"Yu YH, Lin KI. Factors that regulate the generation of antibody-secreting plasma cells. Adv Immunol. 2016;131:61\u201399.","journal-title":"Adv Immunol"},{"key":"1027_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3389\/fimmu.2016.00410","volume":"7","author":"H IJspeert","year":"2016","unstructured":"IJspeert H, van Schouwenburg PA, van Zessen D, Pico-Knijnenburg I, Driessen GJ, Stubbs AP, et al. Evaluation of the antigen-experienced B-cell receptor repertoire in healthy children and adults. Front Immunol. 2016;7:410.","journal-title":"Front Immunol"},{"key":"1027_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/10428190600564803","volume":"47","author":"N Zojer","year":"2006","unstructured":"Zojer N, Kirchbacher K, Vesely M, H\u00fcbl W, Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma. 2006;47:1103\u20139.","journal-title":"Leuk Lymphoma."},{"key":"1027_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10948-w","volume":"10","author":"T Nerreter","year":"2019","unstructured":"Nerreter T, Letschert S, G\u00f6tz R, Doose S, Danhof S, Einsele H, et al. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun. 2019;10:3137.","journal-title":"Nat Commun."},{"key":"1027_CR29","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.4049\/jimmunol.1000831","volume":"185","author":"Y Fukuyama","year":"2010","unstructured":"Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Oishi K, et al. Secretory-IgA antibodies play an important role in the immunity to streptococcus pneumoniae. J Immunol. 2010;185:1755\u201362.","journal-title":"J Immunol."},{"key":"1027_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.bbmt.2017.05.005","volume":"23","author":"H Abdel-Azim","year":"2017","unstructured":"Abdel-Azim H, Elshoury A, Mahadeo KM, Parkman R, Kapoor N. Humoral immune reconstitution kinetics after allogeneic hematopoietic stem cell transplantation in children: a maturation block of IgM memory B cells may lead to impaired antibody immune reconstitution. Biol Blood Marrow Transpl. 2017;23:1437\u201346.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1027_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers7010305","volume":"7","author":"J Worch","year":"2015","unstructured":"Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: What do we know and what can we learn from adults? Cancers. 2015;7:305\u201328.","journal-title":"Cancers"},{"key":"1027_CR32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-3083.2011.02609.x","volume":"74","author":"EJ Schatorj\u00e9","year":"2011","unstructured":"Schatorj\u00e9 EJ, Gemen EF, Driessen GJ, Leuvenink J, van Hout RW, van der Burg M, et al. Age-matched reference values for B-lymphocyte subpopulations and CVID classifications in children. Scand J Immunol. 2011;74:502\u201310.","journal-title":"Scand J Immunol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01027-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T19:08:40Z","timestamp":1667761720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01027-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1027"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01027-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}